GlycoTherapeutics is a drug development startup committed to overcome the efficacy limitations of current cancer immunotherapies. Less than 50% of individuals with cancer receiving immunotherapy obtain a durable response, which is partly due to glycobiology processes that suppress the immune system. Based on over a decade of research, GlycoTherapeutics’ proprietary solution targets these processes by disrupting the interaction of glycans (sugars) that are responsible for immune evasion to maximize the potential of immunotherapy. The company was established in 2022 as a spin-off from Radboud University in the Netherlands and has raised >€1 million in non-dilutive funding.